| General Information |
| Business: |
(Incorporated in Delaware)
We are a Phase 3 pharmaceutical company developing an oral medication to treat obstructive sleep apnea.
Our only clinical drug candidate, AD109, also known as Oxnimbi, is an anti-apneic neuromuscular modulator in a fixed-dose formulation to treat obstructive sleep apnea. AD109 is a combination of a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor. This drug candidate is designed to improve upper airway muscle activity to prevent airway collapse during sleep. We have evaluated Oxnimbi in 1,300 patients in several Phase 3 trials.
Note: Net loss and revenue are for the 12 months that ended on March 31, 2026.
(Note: Apnimed filed its S-1 on July 10, 2026, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure.)
|
| Industry: |
PHARMACEUTICALS |
| Employees: |
65 |
| Founded: |
2017 |
| Contact Information |
| Address |
39 John F. Kennedy Street, 4th Floor Cambridge, MA 02138 |
| Phone Number |
(617) 500-8880 |
| Web Address |
http://www.apnimed.com/ |
| View Prospectus: |
Apnimed |
| Financial Information |
| Market Cap |
|
| Revenues |
$120.15 mil (last 12 months) |
| Net Income |
$-31.83 mil (last 12 months) |
| IPO Profile |
| Symbol |
APMD |
| Exchange |
NASDAQ |
| Shares (millions): |
0.0 |
| Price range |
$0.00 - $0.00 |
| Est. $ Volume |
$100.0 mil |
| Manager / Joint Managers |
BofA Securities/Evercore ISI/Cantor |
| CO-Managers |
|
| Expected To Trade: |
|
|
Status:
|
TBA |
| Quiet Period Expiration Date: |
Available only to Subscribers |
| Lock-Up Period Expiration Date: |
Available only to Subscribers |
| SCOOP Rating |
Available only to Subscribers |
| Rating Change |
Available only to Subscribers |
